Title: Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal Junction
Cancer: A Meta-Analysis of Randomized Controlled Trials
Version: 4 Date: 11 Oct 2024
Reviewer's report:
Thanks to the authors for taking into account my concerns about ATTRACTION-02 and
ATTRACTION-04 trials and including the limitations of their study in the discussion section.
For the record, the following meta-analysis which just came out and should be discussed is
taking into account only  ATTRACTION-4 and concludes that anti-PD1/anti-PDL1 efficiency
is not shown in advanced gastric cancer.
Beshr MS, Beshr IA, Al Hayek M, Alfaqaih SM, Abuajamieh M, Basheer E, Wali
AK, Ekreer M, Chenfouh I, Khashan A, Hassan ET, Elnaami SM, Elhadi M. PD-1/
PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy
Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and
Esophageal Adenocarcinoma: A Meta-Analysis. Clin Oncol (R Coll Radiol). 2024 Sep
21:S0936-6555(24)00385-6. doi: 10.1016/j.clon.2024.09.007. Epub ahead of print. PMID:
39384455.
Title: Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal Junction
Cancer: A Meta-Analysis of Randomized Controlled Trials
Version: 4 Date: 11 Oct 2024
Reviewer's report:
Thanks to the authors for taking into account my concerns about ATTRACTION-02 and
ATTRACTION-04 trials and including the limitations of their study in the discussion section.
For the record, the following meta-analysis which just came out and should be discussed is
taking into account only  ATTRACTION-4 and concludes that anti-PD1/anti-PDL1 efficiency
is not shown in advanced gastric cancer.
Beshr MS, Beshr IA, Al Hayek M, Alfaqaih SM, Abuajamieh M, Basheer E, Wali
AK, Ekreer M, Chenfouh I, Khashan A, Hassan ET, Elnaami SM, Elhadi M. PD-1/
PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy
Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and
Esophageal Adenocarcinoma: A Meta-Analysis. Clin Oncol (R Coll Radiol). 2024 Sep
21:S0936-6555(24)00385-6. doi: 10.1016/j.clon.2024.09.007. Epub ahead of print. PMID:
39384455.
Please review this paper.
user
Title: Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal Junction
Cancer: A Meta-Analysis of Randomized Controlled Trials
Version: 4 Date: 11 Oct 2024
Reviewer's report:
Thanks to the authors for taking into account my concerns about ATTRACTION-02 and
ATTRACTION-04 trials and including the limitations of their study in the discussion section.
For the record, the following meta-analysis which just came out and should be discussed is
taking into account only  ATTRACTION-4 and concludes that anti-PD1/anti-PDL1 efficiency
is not shown in advanced gastric cancer.
Beshr MS, Beshr IA, Al Hayek M, Alfaqaih SM, Abuajamieh M, Basheer E, Wali
AK, Ekreer M, Chenfouh I, Khashan A, Hassan ET, Elnaami SM, Elhadi M. PD-1/
PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy
Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and
Esophageal Adenocarcinoma: A Meta-Analysis. Clin Oncol (R Coll Radiol). 2024 Sep
21:S0936-6555(24)00385-6. doi: 10.1016/j.clon.2024.09.007. Epub ahead of print. PMID:
39384455.
assistant